Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.